Alonso Cruz-Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alonso Cruz-Cruz has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Abel Humberto Villanueva-Compean
Medicina Interna, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social (IMSS) Ciudad de México Mexico
1 shared publication - Alejandra Esquivel-Pineda
Medicina Interna, Centro Médico Nacional Siglo XXI Instituto Mexicano del Seguro Social (IMSS) Ciudad de México Mexico
1 shared publication - Arturo Cérbulo-Vázquez
Laboratorio de Proteómica y Metabolómica, Dirección de Investigación, Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México 06720, Mexico
1 shared publication Barbara Potempa
Department of Oral Immunology and Infectious Diseases, School of Dentistry, University of Louisville
1 shared publication- Carlos J. Rodriguez Hernandez
Center for Microbe and Immunity Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital
1 shared publication Chandra L. Shrestha
Center for Microbe and Immunity Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Gingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection
Physical interactions with bacterial colonizers at mucosal barrier surfaces can have beneficial or detrimental effects on viral infectivity and transmission. The oropharyngeal mucosal surface is a major portal of entry for many pathogenic respiratory viruses, such as respiratory syncytial virus (RSV), and also harbors a rich and diverse microbiome. Whether oropharyngeal bacteria directly or indirectly influence host susceptibility to respiratory viruses remains unknown. Here, we show that Porphyromonas gingivalis , an oral pathobiont, potently and uniquely suppresses airway epithelial antiviral immunity by degrading interferons (IFNs) and transcriptionally repressing multiple IFN-stimulated genes (ISGs), which are essential for providing resistance to viral infection. Despite inducing a state of IFN hyporesponsiveness, we found that P. gingivalis counterintuitively protected against severe infection by RSV and the closely related murine-specific Sendai virus (SeV) in two independent models: human airway bronchial epithelial transwell cultures and airway infection in mice. This protection was conferred by the activity of P. gingivalis cysteine proteases (gingipains) that cleaved envelope glycoproteins on RSV and SeV, thereby impairing their infectious capacity. Thus, our data show a nuanced role for P. gingivalis in modulating host susceptibility to viral infection. While P. gingivalis can significantly inhibit host IFN responses, its proteases preemptively reduce viral infectious capacity, protecting the host from severe damage associated with respiratory infections.
- 30 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (18)
Open AccessGingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection
Physical interactions with bacterial colonizers at mucosal barrier surfaces can have beneficial or detrimental effects on viral infectivity and transmission. The oropharyngeal mucosal surface is a major portal of entry for many pathogenic respiratory viruses, such as respiratory syncytial virus (RSV), and also harbors a rich and diverse microbiome. Whether oropharyngeal bacteria directly or indirectly influence host susceptibility to respiratory viruses remains unknown. Here, we show that Porphyromonas gingivalis , an oral pathobiont, potently and uniquely suppresses airway epithelial antiviral immunity by degrading interferons (IFNs) and transcriptionally repressing multiple IFN-stimulated genes (ISGs), which are essential for providing resistance to viral infection. Despite inducing a state of IFN hyporesponsiveness, we found that P. gingivalis counterintuitively protected against severe infection by RSV and the closely related murine-specific Sendai virus (SeV) in two independent models: human airway bronchial epithelial transwell cultures and airway infection in mice. This protection was conferred by the activity of P. gingivalis cysteine proteases (gingipains) that cleaved envelope glycoproteins on RSV and SeV, thereby impairing their infectious capacity. Thus, our data show a nuanced role for P. gingivalis in modulating host susceptibility to viral infection. While P. gingivalis can significantly inhibit host IFN responses, its proteases preemptively reduce viral infectious capacity, protecting the host from severe damage associated with respiratory infections.
- Open Access
- 9 November 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (12) , 2687-2699
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID‐19 patients with pre‐existing comorbidities
The difficulty in predicting fatal outcomes in patients with coronavirus disease 2019 (COVID‐19) impacts the general morbidity and mortality due to severe acute respiratory syndrome‐coronavirus 2 infection, as it wears out the hospital services that care for these patients. Unfortunately, in several of the candidates for prognostic biomarkers proposed, the predictive power is compromised when patients have pre‐existing comorbidities. A cohort of 147 patients hospitalized for severe COVID‐19 was included in a descriptive, observational, single‐center, and prospective study. Patients were recruited during the first COVID‐19 pandemic wave (April–November 2020). Data were collected from the clinical history whereas immunophenotyping by multiparameter flow cytometry analysis allowed us to assess the expression of surface markers on peripheral leucocyte. Patients were grouped according to the outcome in survivors or non‐survivors. The prognostic value of leucocyte, cytokines or HLA‐DR, CD39, and CD73 was calculated. Hypertension and chronic renal failure but not obesity and diabetes were conditions more frequent among the deceased patient group. Mixed hypercytokinemia, including inflammatory (IL‐6) and anti‐inflammatory (IL‐10) cytokines, was more evident in deceased patients. In the deceased patient group, lymphopenia with a higher neutrophil‐lymphocyte ratio (NLR) value was present. HLA‐DR expression and the percentage of CD39+ cells were higher than non‐COVID‐19 patients but remained similar despite the outcome. Receiver operating characteristic analysis and cutoff value of NLR (69.6%, 9.4), percentage NLR (pNLR; 71.1%, 13.6), and IL‐6 (79.7%, 135.2 pg/mL). The expression of HLA‐DR, CD39, and CD73, as many serum cytokines (other than IL‐6) and chemokines levels do not show prognostic potential, were compared to NLR and pNLR values.
- 9 November 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (12) , 2687-2699
Open AccessPotential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID‐19 patients with pre‐existing comorbidities
The difficulty in predicting fatal outcomes in patients with coronavirus disease 2019 (COVID‐19) impacts the general morbidity and mortality due to severe acute respiratory syndrome‐coronavirus 2 infection, as it wears out the hospital services that care for these patients. Unfortunately, in several of the candidates for prognostic biomarkers proposed, the predictive power is compromised when patients have pre‐existing comorbidities. A cohort of 147 patients hospitalized for severe COVID‐19 was included in a descriptive, observational, single‐center, and prospective study. Patients were recruited during the first COVID‐19 pandemic wave (April–November 2020). Data were collected from the clinical history whereas immunophenotyping by multiparameter flow cytometry analysis allowed us to assess the expression of surface markers on peripheral leucocyte. Patients were grouped according to the outcome in survivors or non‐survivors. The prognostic value of leucocyte, cytokines or HLA‐DR, CD39, and CD73 was calculated. Hypertension and chronic renal failure but not obesity and diabetes were conditions more frequent among the deceased patient group. Mixed hypercytokinemia, including inflammatory (IL‐6) and anti‐inflammatory (IL‐10) cytokines, was more evident in deceased patients. In the deceased patient group, lymphopenia with a higher neutrophil‐lymphocyte ratio (NLR) value was present. HLA‐DR expression and the percentage of CD39+ cells were higher than non‐COVID‐19 patients but remained similar despite the outcome. Receiver operating characteristic analysis and cutoff value of NLR (69.6%, 9.4), percentage NLR (pNLR; 71.1%, 13.6), and IL‐6 (79.7%, 135.2 pg/mL). The expression of HLA‐DR, CD39, and CD73, as many serum cytokines (other than IL‐6) and chemokines levels do not show prognostic potential, were compared to NLR and pNLR values.